Alessandro Di Domizio - JoVE Visualize

Showing results (11-20 of 13) with videos related to

Pageof 2

Sort By:

You have reached the last page of results.This site can display upto 13 results.

Biology|January 21, 2022

MV1035 Overcomes Temozolomide Resistance in Patient-Derived Glioblastoma Stem Cell LinesAlessio Malacrida, Alessandro Di Domizio, Angela Bentivegna, et al.

Biochemical and Biophysical Research Communications|June 23, 2009

Selective cytotoxicity of a bicyclic Ras inhibitor in cancer cells expressing K-Ras(G13D)Alessandro Palmioli, Elena Sacco, Cristina Airoldi, et al.

Frontiers in Pharmacology|January 18, 2024

Fraisinib: a calixpyrrole derivative reducing A549 cell-derived NSCLC tumor <i>in vivo</i> acts as a ligand of the glycine-tRNA synthase, a new molecular target in oncologyIméne Ben Toumia, Tiziana Bachetti, Leila Chekir-Ghedira, et al.

Pageof 2

Showing results (11-20 of 13) with videos related to

Sort By:

Pageof 2

You have reached the last page of results.This site can display upto 13 results.

Biology|January 21, 2022

MV1035 Overcomes Temozolomide Resistance in Patient-Derived Glioblastoma Stem Cell LinesAlessio Malacrida, Alessandro Di Domizio, Angela Bentivegna, et al.

Biochemical and Biophysical Research Communications|June 23, 2009

Selective cytotoxicity of a bicyclic Ras inhibitor in cancer cells expressing K-Ras(G13D)Alessandro Palmioli, Elena Sacco, Cristina Airoldi, et al.

Frontiers in Pharmacology|January 18, 2024

Fraisinib: a calixpyrrole derivative reducing A549 cell-derived NSCLC tumor <i>in vivo</i> acts as a ligand of the glycine-tRNA synthase, a new molecular target in oncologyIméne Ben Toumia, Tiziana Bachetti, Leila Chekir-Ghedira, et al.

Pageof 2